Close Menu

single-molecule sequencing

Taiwan-based Personal Genomics, which is developing a new single-molecule sequencing platform, has previously sued PacBio for patent infringement in the US.

The sequencing firm reported total revenues of $15.6 million, with instrument revenue negatively impacted by shutdowns precipitated by COVID-19.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.

The Delaware jury said Oxford Nanopore had infringed three patents, but also found that they were invalid, mostly because they were not enabled.

The methods exploit a feature of Oxford Nanopore's technology that ejects molecules mid-read, enabling a new level of control over human DNA sequencing runs.

All three methods build on the use of methyltransferases to mark accessible regions of the genome, using nanopore sequencing to detect the modifications.

PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.

Full-year 2019 revenues grew 16 percent and the firm booked $18 million in other income from Illumina, before their acquisition deal fell apart.

ONT called Illumina's revised remedies proposal an "illusory offer" that doesn't offset the anticompetitive effects of an Illumina-PacBio merger.

Strong growth in instrument revenue, driven by sales of the Sequel II system, was tempered by decreased consumable revenue as customers transitioned to the new platform.

Pages

Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.

Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.

Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.

In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.